Biomx

Biomx Equity Growth

The Year-over-Year Equity Growth of Biomx (PHGE) as of Oct 25, 2026 is -105.39 %. In the previous year, Year-over-Year Equity Growth was 683.77 % — a change of -115.41% (lower).

Equity Growth

-105.39 %

YoY

-115.41%

Last updated:

Year-over-Year Equity Growth of Biomx is 2025 -105.39 % . Year-over-Year Equity Growth of Biomx was 2024 683.77 % . It decreases by -115.41% lower compared to the previous year.

The Biomx Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
513.62 USD
Jan 1, 2019
19.37 USD
Jan 1, 2020
-31.95 USD
Jan 1, 2021
-17.29 USD
Jan 1, 2022
-55.74 USD
Jan 1, 2023
-85.36 USD
Jan 1, 2024
683.77 USD
Jan 1, 2025
-105.39 USD
The Biomx Equity Growth history
YEAREquity GrowthYoY
-105.39 %-115.41%
683.77 %-901.08%
-85.36 %+53.13%
-55.74 %+222.46%
-17.29 %-45.90%
-31.95 %-264.95%
19.37 %-96.23%
513.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomx Stock analysis

What does Biomx do? BiomX Ltd develops bacteriophage-based therapies targeting dysbiosis-related diseases, focusing on natural and engineered phage solutions. The company's pipeline includes BX001 for acne-prone skin, BX002 for IBD bacterial targets, and BX003 for Klebsiella pneumoniae strains. BiomX discovers and validates bacterial targets to customize phage compositions, aiming to treat conditions like inflammatory bowel disease, primary sclerosing cholangitis, and cancer through targeted bacterial destruction. The firm creates therapies for skin appearance issues and chronic diseases, with BX001 addressing acne, BX002 targeting IBD onset bacteria, and BX003 focusing on specific Klebsiella pneumoniae strains. BiomX's approach involves developing both natural and engineered phage cocktails tailored to bacterial targets, ensuring precise treatment for microbiome-related conditions without naming specific buyers or segments. BiomX Ltd's revenue model relies on the development and commercialization of its phage therapy pipeline. The company's products BX001, BX002, and BX003 are designed to treat specific bacterial-related conditions, with BX001 targeting skin appearance, BX002 for IBD, and BX003 for Klebsiella pneumoniae, all developed through customized phage compositions against validated bacterial targets. Biomx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomx stock

Year-over-Year Equity Growth of Biomx is -105.39 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Biomx since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Biomx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biomx

All Key Metrics — Biomx